The future of global
cannabis genetics


We envisioned medcann Pharma as a global player in formalized cannabis genetics, leveraging our main competitive advantages:

Regulatory asset

Our people

Research, Development, and Innovation projects

The best quality genetics

Our range of registered cultivars, and characterization expertise, allows us to develop excellent quality genetics due to their cannabinoid and terpene structure, and performance under several growing conditions.

Breeding goals for the genetics under development:

To provide much more resistant cultivars through testing in challenging outdoor conditions.

To adapt and develop genetics to the climate we chose within a framework of continuous R&D and Breeding programs, to offer the best quality in terms of variety, productivity, and resilience.

To be the most cost-effective supplier to cultivators worldwide.

We have an ambitious Genetic Registration Program to ensure the continuous development of new genetics meeting market needs and progress in technical and scientific research.

medcann license portfolio

Colombian regulation defines non-psychoactive cannabis as that with concentrations of THC (Tetrahydrocannabidol) less than 1%.

medcann Pharma has all licenses granted by the Colombian authorities. Likewise, the company has the respective registries with the Colombian Agricultural Institute – ICA – for the production, export, trading and / or importation of seeds for sowing in the country. In 2018, the company obtained the registration as Seed Producer (asexual) of psychoactive and non-psychoactive cannabis, thus becoming one of the first in the country to achieve this certification.

Clients and Projects



If you are looking
for formally registered
cannabis genetics